Updated 21 October 2026.
A product can be CE marked, registered with the MHRA and available to an NHS organisation without the MHRA having endorsed every clinical claim made about it. Another product can hold an FDA designation without being authorised for commercial distribution. These distinctions are not semantic trivia. They determine what a clinician can reasonably infer from the evidence presented.
The best way to interpret regulatory language is to ask what decision was made, by whom, about which product and for what intended use. Words such as "approved", "certified" and "validated" become misleading when detached from those details.
FDA clearance is a specific route, not a generic accolade
The FDA's description of device approvals and clearances explains the distinction between 510(k) clearance and premarket approval. A 510(k) submission generally demonstrates substantial equivalence to a legally marketed predicate device. That is a substantive regulatory assessment, but it is not the same process as premarket approval, or PMA.
PMA involves assessment of safety and effectiveness evidence for the intended use and is associated with higher-risk devices. It should not be described as the necessary route for every useful medical technology. Different products require different pathways because their risks and regulatory histories differ.
A clinician reviewing an AI announcement should locate the actual device record and decision summary where available. A clearance for one imaging task does not automatically extend to another anatomy, population or clinical setting merely because the supplier uses a shared model architecture.
De Novo and Breakthrough status mean different things
The De Novo pathway provides a route for certain novel devices without a suitable legally marketed predicate. It establishes an appropriate classification and controls when the evidence supports that outcome. It is a marketing-authorisation route, not simply a company entering a promising research programme.
By contrast, the FDA's Breakthrough Devices Program is intended to support development and review of eligible technologies. Designation should not be reported as equivalent to clearance, approval or a finding that a device is superior to every alternative.
These distinctions also matter when comparing companies. A product with a different regulatory route is not automatically more advanced, less responsible or less clinically useful. The relevant comparison is whether each product has the evidence and authorisation appropriate to its actual intended task.
What CE marking establishes
For a medical device, CE marking concerns conformity with the applicable European requirements. The assessment process depends on the device and its risk class. Many Class I devices use manufacturer self-declaration, with exceptions requiring notified-body involvement; higher-risk routes ordinarily involve an independent notified body.
Software classification deserves particular care. European Commission guidance on medical-device software explains qualification and classification, including Rule 11. Not every healthcare application is a medical device, and not every medical software product is necessarily Class IIa. The decision follows the intended purpose and the applicable rules.
A certificate or declaration must also be read at product level. A supplier's certified quality system is not a certificate covering every application it might later release. The same principle applies when one interface combines documentation, coding, reference, scheduling and recommendation functions.
What changed in Great Britain in October 2026
The government's CE-recognition outcome confirms an intention to legislate for indefinite recognition of devices complying with EU MDR and EU IVDR, while separately addressing legacy transitions. This removes the assumption that all such manufacturers must eventually obtain UKCA solely to retain Great Britain access.
It does not abolish UKCA, turn expired documentation into permanent conformity, or merge Great Britain's rules with Northern Ireland's arrangements. The implementation details and existing obligations remain relevant while the announced changes are put into effect.
For buyers, the practical change is greater long-term certainty around a recognised route. It is not a reason to stop asking for evidence, product identity or the limitations of the intended purpose. The regulatory badge still describes a defined scope.
MHRA registration is not MHRA approval
The MHRA registration guidance explains the registration obligations relevant to placing devices on the Great Britain market. Registration should not be presented as an independent endorsement of the device's comparative clinical performance.
A useful procurement record should therefore keep registration separate from conformity documentation. Include the legal manufacturer, product and version, intended use, applicable mark, declaration or certificate, and registration details. Where a representative is required, record that arrangement too.
This distinction applies to iatroX as much as to competitors. A supplier's statement about registration or class should never be converted into a claim that the regulator has personally tested its generated answers. The appropriate response is to inspect the scope and evidence, not to repeat a stronger marketing interpretation.
NICE asks another set of questions
NICE evaluation concerns the evidence and value associated with technologies and their use in care. It is not interchangeable with market-access conformity assessment. The NICE evidence standards framework for digital health technologies helps clarify the types of evidence that can support evaluation.
A NICE recommendation should be read in full, including the population, conditions of use and any evidence-generation requirements. A reference to NICE guidance inside an AI answer is something else entirely: it means the answer cites a clinical source, not that NICE has assessed or recommended the AI product.
Likewise, a claim that a product "follows NICE" does not prove that it retrieves the correct passage, interprets exceptions accurately or remains current. Source use and product evaluation are different layers of assurance.
A practical way to read the next AI announcement
Start with the clinical output. Is the software producing a note, suggesting a diagnosis, supporting a treatment decision or providing general information? Then identify the jurisdiction and the exact regulatory claim. Only after those are clear should you compare evidence, workflow fit and cost.
Avoid a single ordered ladder in which every label sits above or below the others. Registration, conformity, authorisation and health-technology evaluation perform different functions. A business can satisfy one and still need to address the others.
The same discipline improves everyday reference use. iatroX's methodology describes how its clinical information and learning workflows are designed. That is material to examine, not a substitute for checking the cited recommendation or evidence relevant to the question in front of you.
Frequently asked questions
Does CE marking mean a device is MHRA approved?
No. CE conformity and MHRA registration are distinct. Great Britain recognises qualifying CE routes, but recognition and registration should not be described as a blanket MHRA endorsement of performance.
Does quoting NICE make an AI tool NICE recommended?
No. Citing a NICE guideline is different from a NICE evaluation of the product. Check for an actual recommendation and its conditions rather than inferring one from source links.
Is Class IIa a guarantee of greater accuracy than Class I?
No. Classification reflects the applicable regulatory rules and intended purpose, not a universal comparative-accuracy score. Products with different tasks cannot be ranked reliably by class alone.
Make provenance part of the comparison
Explore Ask-iatroX and inspect the sources behind a clinical answer rather than relying on regulatory shorthand alone.